Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release

Cancer Lett. 1999 Nov 1;146(1):45-51. doi: 10.1016/s0304-3835(99)00227-x.

Abstract

The mu3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the mu3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific mu opioid receptor transcripts are present in lung carcinoma and other cells with the mu3 profile. Our findings identify a unique role for the mu3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Dihydromorphine / metabolism
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / pharmacology
  • Humans
  • Lung / chemistry*
  • Lung Neoplasms / chemistry*
  • Nitric Oxide / biosynthesis*
  • RNA, Messenger / analysis
  • Receptors, Opioid, mu / analysis*
  • Receptors, Opioid, mu / genetics

Substances

  • RNA, Messenger
  • Receptors, Opioid, mu
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • Nitric Oxide
  • Dihydromorphine